Keynote 024 Orr. Consistent with results from keynote‐024 overall, first‐line pembrolizumab improved progression‐free survival and overall survival vs chemotherapy with. On june 17, 2019, the food and drug administration granted accelerated approval to pembrolizumab (keytruda, merck) for patients with metastatic small cell lung cancer.
On june 17, 2019, the food and drug administration granted accelerated approval to pembrolizumab (keytruda, merck) for patients with metastatic small cell lung cancer. A total of 103 patients were enrolled and received.